These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 6780643

  • 1. Factor VIII-related activities in therapeutic concentrates.
    Barrowcliffe TW, Kemball-Cook G, Morris G, Holt JC, Furlong RA, Peake IR.
    J Lab Clin Med; 1981 Mar; 97(3):429-38. PubMed ID: 6780643
    [Abstract] [Full Text] [Related]

  • 2. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM.
    Wien Klin Wochenschr; 1982 Oct 15; 94(19):509-14. PubMed ID: 6818773
    [Abstract] [Full Text] [Related]

  • 3. In vitro characterization of various factor VIII concentrates.
    Yoshioka A, Shima M, Nishino M, Yoshikawa N, Fukui H.
    Arzneimittelforschung; 1987 Jul 15; 37(7):753-6. PubMed ID: 3118888
    [Abstract] [Full Text] [Related]

  • 4. Standardization of Factor VIII-III. Establishment of a stable reference plasma for Factor VIII-related activities.
    Barrowcliffe TW, Tydeman MS, Kirkwood TB, Thomas DP.
    Thromb Haemost; 1983 Oct 31; 50(3):690-6. PubMed ID: 6417818
    [Abstract] [Full Text] [Related]

  • 5. Recent advances in hemophilia.
    Tann G.
    Southeast Asian J Trop Med Public Health; 1979 Jun 31; 10(2):218-28. PubMed ID: 524146
    [Abstract] [Full Text] [Related]

  • 6. Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate.
    Over J, Bouma BN, van Mourik JA, Sixma JJ, Vlooswijk R, Bakker-Woudenberg I.
    J Lab Clin Med; 1978 Jan 31; 91(1):32-46. PubMed ID: 618989
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.
    Thromb Haemost; 2007 Jun 31; 97(6):922-30. PubMed ID: 17549293
    [Abstract] [Full Text] [Related]

  • 8. Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.
    Prowse CV, Griffin B, Pepper DS, Dickson AJ, McQuillan TA, Dickson IH, Foster PR.
    Thromb Haemost; 1981 Oct 31; 46(3):597-601. PubMed ID: 6797090
    [Abstract] [Full Text] [Related]

  • 9. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G, Carretero M, Magallón M, Quintana M, Arnau C, Castillo R, Aznar-Salatti J.
    Haematologica; 1998 Nov 31; 83(11):1009-14. PubMed ID: 9864923
    [Abstract] [Full Text] [Related]

  • 10. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC, Pepper DS, Griffin B.
    Thromb Haemost; 1981 Aug 28; 46(2):543-6. PubMed ID: 6795742
    [Abstract] [Full Text] [Related]

  • 11. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
    Favaloro EJ, Bukuya M, Martinelli T, Tzouroutis J, Duncan E, Welldon K, Collecutt M, Aumann H, Thom J, Gilmore G.
    Thromb Haemost; 2002 Mar 28; 87(3):466-76. PubMed ID: 11916080
    [Abstract] [Full Text] [Related]

  • 12. Homo- and heterogeneous forms of human factor VIII.
    Vukovich TC.
    Thromb Haemost; 1982 Aug 24; 48(1):98-100. PubMed ID: 6814000
    [Abstract] [Full Text] [Related]

  • 13. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U, Metzner HJ, Müller HG.
    Semin Thromb Hemost; 2006 Sep 24; 32(6):626-35. PubMed ID: 16977573
    [Abstract] [Full Text] [Related]

  • 14. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 24; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 15. Heterogeneity of molecular size of factor VIII/von Willebrand factor in von Willbrand's disease.
    Mikami S, Takahashi Y, Nishino M, Okubo Y, Fukui H.
    Thromb Haemost; 1981 Jun 30; 45(3):272-5. PubMed ID: 6792740
    [Abstract] [Full Text] [Related]

  • 16. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL, Siekmann J, Schwarz HP.
    Semin Thromb Hemost; 2002 Apr 30; 28(2):149-60. PubMed ID: 11992238
    [Abstract] [Full Text] [Related]

  • 17. Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease.
    Meyer D, Obert B, Pietu G, Lavergne JM, Zimmerman TS.
    J Lab Clin Med; 1980 Apr 30; 95(4):590-602. PubMed ID: 6965697
    [Abstract] [Full Text] [Related]

  • 18. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S, Carlson M, Hillarp A.
    Haemophilia; 2004 May 30; 10(3):243-9. PubMed ID: 15086321
    [Abstract] [Full Text] [Related]

  • 19. Factor VIII: C and factor VIII R: Ag in Argentine hemorrhagic fever.
    Molinas FC, Maiztegui JI.
    Thromb Haemost; 1981 Aug 28; 46(2):525-7. PubMed ID: 6795740
    [Abstract] [Full Text] [Related]

  • 20. Characterization of factor VIII related protein synthesized by human endothelial cell: a study of structure and function.
    Chan V, Chan TK.
    Thromb Haemost; 1982 Oct 29; 48(2):177-81. PubMed ID: 6817445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.